References
- Goddard NL, Joseph CA, Watson JM, Ellis JS, Zambon MC. Three years of low influenza activity — no reason for complacency. Commun. Dis. Public Health 6,128–132 (2003).
- Izurieta HS, Thompson WW, Kramarz P. et aL Influenza and the rates of hospitalization for respiratory disease among infants and young children. N EngL J. Med. 342,232-239 (2000).
- Gamblin SJ, Haire LF, Russell RJ et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303,1838–1842 (2004).
- Webster RG, Hay AJ. The H5N1 influenza outbreak in Hong Kong: a test of pandemic preparedness. In: Textbook of influenza. Blackwell Scientific Publications, London, UK, 561–565 (1998).
- Centres for Disease Control and Prevention. Guideline for infectious control in healthcare personnel, 1998. Infect. Control Hosp. EpidemioL 19,410–459 (1998).
- Long CE, Hall CB, Cunningham CK et al Influenza surveillance in community-dwelling elderly compared with children. Arch. Fam. Med. 6,459–465 (1997).
- Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population on the course of an A2/Hong Kong influenza epidemic. Bull. World Health Org. 41,537-542 (1969).
- Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am.j EpidemioL 115,736–751 (1982).
- Nguyen-Van-Tam JS, Hampson AW. The.
- •epidemiology and clinical impact of pandemic influenza. Vaccine 21 1762–1768 (2003).
- Gurfinkel EP, de la Fuente RL, Mendiz 0, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J. 25,25-31 (2004).
- Nichol KL, Nordin J, Mullooly J et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke in the elderly. N Engl. I Med. 348, 1322–1332 (2003).
- Hak E, Nordin J, Wei F et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin. Infect. Dis. 35,370-377 (2002).
- Loughlin J, Poulis N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics21, 273–283 (2003).
- Morishima R, Togashi T, Yokota S et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin. Infect. Dis. 35,512–517 (2002).
- Weinburg GA, Erdman DD, Edwards KM et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. Infect. Dis. 189,706–710 (2004).
- Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Ce1169, 517–528 (1992).
- Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine and rimantadine for preventingand treating influenza A in adults. In: The Cochrane library, Issue 4. John Wiley and Sons Ltd, Chichester, UK (2001).
- Freund B, Gravenstein S, Elliot M, Miler I. Zanamivir: a review of clinical safety. Drug Safety4, 267–281 (1999).
- Murphy KR, Eivindson A, Pauksens K et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin. Drug Invest. 20,337–349 (2000).
- Cooper NJ, Sutton AJ, Abrams KR et al Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized controlled trials. Br. Med. J. 326,1235 (2003).
- Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. 20,127–133 (2001).
- Gerdil C. The annual production cycle for influenza vaccine. Vaccine 21,1776–1779 (2003).
- Palashe AM, Scheepers HSJ, De Regt V et al Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98,115–125 (1999).
- Wagner DK, Clements ML, Reimer CB et al Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin. Microbiol 25,559–562 (1987).
- Beyer WEP, Palache AM, de Jong JC.
- ••Osterhaus ADME. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20, 1340–1353 (2002).
- Lasky T, Terracciano GJ, Magder L et al. The Guillain—Barré syndrome and the 1993 and 1993–1994 influenza vaccines. N. Engl. J. Med. 339,1797-1802 (1998).
- Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain—Barre syndrome in the United States, 1979–1980 and 1980–1981. Lack of an association with influenza vaccination. JAMA 248,698–700 (1982).
- Mbawuike IN, Piedra PA, Cate TR, Couch RB. Cytotoxic T-lymphocyte responses of infants after natural infection or immunization with live cold-recombinant or inactivated influenza A virus vaccine. J. Med. Viro150, 105–111 (1996).
- Vu T, Farish S, Jenkins M, Kelly H. A. meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20, 1831–1836 (2002).
- Heikkinen T, Ruuskanen 0, Waris M et al.
- •Influenza vaccination in the prevention of acute otitis media in children. Am. J Dis. Child. 145,445-448 (1991).
- Neuzil KM, DuPont WD, Wright PF. Edwards KM. Efficay of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experiences. Pediatr. Infect. Dis. J 20, 733-740 (2001).
- Maeda T, Shintani Y, Nakano K, Terashima K, Yamada Y. Failure of inactivated influenza A vaccine to protect healthy children aged 6–24 months. Pediatr. Intl 46,122 (2004).
- Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20,2562–2578 (2002).
- Nichol KL, Wuornema J, von Sternberg T. Benefits of influenza vaccination for low-intermediate-, and high-risk senior citizens. Arch. Intern. Med. 158, 1769–1776 (1998).
- White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school aged children. Pediatrics 103, E73 (1999).
- Fitner KA, Shortridge KF, McGhee SM, Hedley AJ. Cost-effectiveness study on influenza prevention in Hong Kong. Health Policy56, 215–234 (2001).
- Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatrics 136,168–175 (2000).
- Piedra PA. Safety of the trivalent, cold- adapted influenza vaccine (CAIV-T) in children. Semin. Pediatr. Infect. Dis. 13, 90–96 (2002).
- Piedra PA, Yan L, Kotloff K etal. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110, 62–72 (2002).
- Wright PF, Karzon DT. Live attenuated influenza vaccines. Frog. Med. Virol 34, 70–88 (1987).
- Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated, intranasal influenza virus vaccine in healthy, adult workers: a randomized controlled JAMA 282,137–144 (1999).
- Belshe RB, Mendelman PM, Treanor J.
- ••et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl. J Med. 338,1405-1412 (1998).
- Update: Influenza activity — United States, 1997-98 season. MMWR Weekly 47, 196–200 (1998).
- Powers DC, Fries LF, Murphy BR, Thumar B, Clements ML. In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccines in inducing serum or secretory antibodies or local immunological memory. J. Clin. Microbiol 29,498–505 (1991).
- Targonski PV, Poland GA. Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly? Drugs Aging 21, 349–359 (2004).
- Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a nonadjuvanted influenza vaccine in nonelderly adults. Vaccine 21, 4234–4237 (2003).
- Banzhoff A, Nacci 13, Podda A. A new MF59 adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology49,177–184 (2003).
- Bungener L, Idema J, ter Veer W et al Virosomes in vaccine development: induction of cytotoxic T-lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res. 12,155–163 (2002).
- De Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low prevaccination antibody titers. Virus Res. 103,139–145 (2004).
- Pregliasco F, Mensi C, Serpilli W et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano). 13,38–43 (2001).
- Neumann G, Watanabe T, Ito H et al.
- •Generation of influenza A viruses entirely from cloned cDNA. Proc. Natl Acad. Sci. USA 96,9345-9350 (1999).
- Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732–1737 (2001).
- Krug RM. The potential use of influenza virus as an agent for bioterrorism. Antiviral Res. 57,147–150 (2003).
- Montagnon BJ, Fanget B, Nicholas AJ. The large-scale cultivation of Vero cells in microcarrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev. Biol. Stand. 47–55 (1987).
- Bruhl P, Kerschbaum, Kistner 0 et al.
- •Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine. Vaccine 19,1149-1158 (2001).
- Kroeman M, Paget WJ, van Essen GA. Influenza vaccination in Europe: an inventory of strategies to reach target populations and optimise vaccination uptake. Euro. Surveil]: 8,130-138 (2003).
Websites
- Turner D, Wailoo A, Nicholson K etal. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. www.nice.org.uk/pdf/influenzaasrep.pdf Accessed July, 2004.
- Crofts JP, Joseph CA, Zambon M et al. Influenza surveillance in the United Kingdom: October 2002 to May (2003). CDR Weekly14 (10), (2004). www.hpa.org.uldcdr/PDFfiles/2004/cdR10 04.pdf.
- Chui SS, Tse CY, Lau YL, Peiris M. Influenza A infection is an important cause of febrile seizures. Pediatrics 108, E63 (2001) www.pediatrics.orgicgi/contentifull/108/4/.
- Zanamivir, oseltamivir and amantadine for the treatment and prophylaxis of influenza. NICE 2002 www.nice.org.uldpdf/FAD_zanamivir.pdf Accessed July, 2004.
- MMWR Recommendations and Reports. Prevention and control of influenza — recommendations of the Advisory Committee in Immunization Practices (ACIP). MMWR 52 (RR08), 1–36 (2003). www.cdc.goviminwripreviewimmwrhtmYr R5208a1.htm Accessed July, 2004.
- CDC. Influenza antivirals medications: interim chemoprophylaxis and treatment guidelines (2003). wwwcdcgovifluiprofessionals/pdVantiviralg uidpdf2004 Accessed July, 2004.